Cytochrome p4501A1 gene variants as susceptibility marker for prostate cancer

Cancer Biomarkers

Volumn 1, Issue 4-5, 2005, Pages 251-258

  Vijayalakshmi, K ^a   Vettriselvi, V ^a   Krishnan, M ^a   Shroff, Sunil ^a   Jayanth, Vikram R ^a   Paul, Solomon F D ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

3'UTR; CytochromeP4501A1; polymorphisms; prostate cancer

Indexed keywords

CYTOCHROME P450 1A1; RESTRICTION ENDONUCLEASE; TUMOR MARKER;

AGED; ARTICLE; CANCER STAGING; CARCINOMA; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; ONSET AGE; PATHOLOGY; PROSTATE TUMOR; RISK;

AGE OF ONSET; AGED; AGED, 80 AND OVER; CARCINOMA; CYTOCHROME P-450 CYP1A1; DNA RESTRICTION ENZYMES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 34249827418     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2005-14-508     Document Type: Article

References (33)

1. C. Acevedo, J.L. Opazo, C. Huidobro, J. Cabezas, J. Iturrieta and L.Q. Sepulveda, Positive Correlation between single or combined genotypes of CYP1A1and GSTM1 in relation to prostate cancer in Chilean people, The Prostate 57 (2003), 111-117.
2. H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman and K. Alexandrov, Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier to tobacco-related cancers, Cancer Epidemiol. Biomarkers Prev. 9 (2000), 3-28.
3. S. Buch, A. Kotekar, D. Kawle and R. Bhisey, Polymorphisms at CYP and GST loci Prevalance in the Indian population, Eur J Clin Pharmacol 57 (2001), 553-555.
4. I. Cascorbi, J. Brockmoller and I. Roots, A C4887A polymorphism in exon 7 of human CYP 1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility, Cancer Res 56 (1996), 4965-4969.
5. E.L. Cavalieri, P. Devanesan, M.C. Bosland, A.F. Badawi and E.G. Rogan, Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer, Carcinogenesis 23 (2002), 329-333.
6. B.L. Chang, S.L. Zheng, S.D. Isaacs, A. Turner, G.A. Hawkins, K.E. Wiley, E.R. Bleecker, P.C. Walsh, D.A. Meyers, W.B. Isaacs and J. Xu, Polymorphisms in the Cyp1A1 gene are associated with prostate cancer risk, Int. J. Cancer. 106 (2003), 375-378.
7. S.K. Clinton, C. Emenhiser, S.J. Schwartz, D.G. Bostwick, A.W. Williams, B.J. Moore and J.W. Erdman, Cis-trans lycopene isomers, carotenoids, and retinol in the human prostate, Cancer Epidemiol Biomarkers Prev 5 (1996), 823-833.
8. F. Crofts, E. Taioli, J. Trachman, D. Currie, P. Toniolo and S.J. Garte, Functional significance of different human CYP1A1 genotypes, Carcinogenesis 15 (1994), 2961-2963.
9. R. Crofts, G.N. Cosma, E. Taioli, D.C. Currie, P.T.Toniolo and S.J. Garte, A novel CYP1A1 gene polymorphism in African-Americans, Carcinogenesis 14 (1993), 1729-1731.
10. H. Deneo-Pellegrini, E.D. Stefani, A. Ronco and M. Mendilaharsu, Foods, nutrients and prostate cancer: a case-control study in Uruguay, Br J Cancer 80 (1999), 591-597.
11. V. Gajalakshmi, V. Shanta and R. Swaminathan, Cancer registration in India, Asian Pacific J Cancer Prev 2 (2001), IACR Supplement, 13.
12. P.H. Gann, C.H. Hennekens, J. Ma, C. Longcope and M.J. Stampfer, A prospective study of sex hormone levels and risk of prostate cancer, J Natl Cancer Inst 88 (1996), 1118-1126.
13. P.H. Gann, J. Ma, E. Giovannucci, W. Willett, F.M. Sacks, H. Charles, Hennekens and M.J. Stampfer, Lower Prostate Cancer risk in men with elevated plasma lycopene levels: Results of a prospective, Cancer Res 59 (1999), 1225-1230.
14. S. Garte, The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1, Carcinogenesis 19 (1998), 1329-1332.
15. S. Garte, L. Gaspari, A.K. Alexandrie, C. Ambrosone, H. Autrup, J.L. Autrup, H. Baranova, L. Bathum, S. Benhamou, P. Boffetta, C. Bouchardy, K. Breskvar, J. Brockmoller, I. Cascorbi et al., Metabolic gene polymorphism frequencies in control populations, Cancer Epidemiol Biomarkers Prev 10 (2001), 1239-1248.
16. H. Gronberg, Prostate cancer epidemiology, The Lancet 361 (2003), 859-864.
17. A.W. Hsing, L. Tsao and S.S. Devesa, International trends and patterns of prostate cancer incidence and mortality, Int. J. Cancer. 85 (2000), 60-67.
18. B.R. Konety, C.S. Johnson, D.L. Trump and R.H. Getzenberg, Vitamin D in the prevention and treatment of prostate cancer, Semin Urol Oncol 17 (1999), 77-84.
19. V.N. Kristensen, E.H. Kure, B. Erikstein, N. Harada and A. Borresen-Dale, Genetic susceptibility and environmental estrogen-like compounds, Mutation Res 482 (2001), 77-82.
20. M. Landstrom, J.X. Zhang, G. Hallmans, P. Aman, A. Bergh, J.E. Damber, W. Mazur, K. Wahala and H. Adlercreutz, Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats, Prostate 36 (1998), 151-161.
21. P.P. Majumder and B.N. Mukherjee, Genetic diversities and affinities among Indian populations: an overview, in: Human Population Genetics, P.P. Majumder, ed., Plenium Press, Newyork, 1993, pp. 255-275.
22. C.R. Mehta, N.R. Patel and R. Gray, A network algorithm for performing Fischer's Exact test in rxc contingency tables, Journal Of American Statistical Association 78 (1983), 427-434.
23. M. Murata, T. Shiraishi, K. Fukutome, M. Watanabe, M. Nagao, Y. Kubota, H. Ito, J. Kawamura and R. Yatani, Cytochrome P4501A1 and Glutathione Transferase M1 Genotypes as Risk Factors for Prostate Cancer in Japan, Jpn. J. Clin. Oncol. 28 (1998), 657-660.
24. M. Murata, M. Watanabe, M. Yamanaka, Y. Kubota, H. Ito, M. Nagao, T. Katoh, T. Kamataki, J. Kawamura, R. Yatani and T. Shiraishi, Genetic polymorphisms in Cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, Glutathione s-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population, Cancer Lett. 165 (2001), 171-177.
25. N.S. Murthy and A. Mathew, Cancer epidemiology, prevention and control, Current Science 86 (2004), 518-527.
26. D.R. Nelson, L.Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen and D.J. Waxman, P450 Superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics 6 (1996), 1-42.
27. H. Raunio, P.K. Husgafvel, S. Anttila, E. Hietanen, A. Hirvonenand and O. Pelkonen, Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review, Gene 159 (1995), 113-121.
28. A.V. Sarma and D. Schottenfeld, Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001, Semin Urol Oncol 20 (2002), 3-9.
29. H. Shimizu, R.K. Ross, L. Bernstein, R. Yatani, B.E. Henderson and T.M. Mack. Cancers of the prostate and breast among Japanese and white immigrants in Losangeles County, Br J Cancer 63 (1991), 963-966.
30. K. Suzuki, H. Matsui, H. Nakazato, H. Koike, H. Okugi, M. Hasumi, N. Ohtake, S. Nakata, T. Takei, M. Hatori, K. Ito and H. Yamanaka, Association of the genetic polymorphism in Cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case control study, Cancer Letters 195 (2003), 177-183.
31. J.W. Van der Gulden, A.L. Verbeek and J.J. Kolk, Smoking and drinking habits in relation to prostate cancer, Br J Urol 73 (1994), 382-389.
32. Y. Wang, D. Sudilovsky, B. Zhang, P.C. Haughney, M.A. Rosen, D.S.Wu, T.J. Cunha, R. Dahiya, G.R. Cunha and S.W. Hayward, A human prostatic epithelial model of hormonal carcinogenesis, Cancer Res 61 (2001), 6064-6072.
33. J.A.Williams, F.L. Martin, G.H. Muir, A. Hewer, P.L. Grober and D.H. Phillips, Metabolic activation of carcinogens and expression of various cytochrome P450 in human prostate tissue, Carcinogenesis 21 (2000), 1683-1689.